

Eloxx Pharmaceuticals, Inc. (ELOX)

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001035354

Eloxx Pharmaceuticals, Inc.		
ELOX; healthcare		
Grade	None 2 of 14 inputs computable; 7 are required	Share price, twelve months to the rescansplit-adjusted close; the letter is fixed at the rescans that set it 
Reliability	0.76 AUC filers with under \$12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025	
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	under \$12.5M assets total assets \$5.3M	
Standard universe	outside revenue above \$1M and assets above \$10M	
Warnings	late filer, thin data, degenerate inputs; fortress balance sheet not computable: dilution, short runway, distress	
Inputs computable	2 of 14	
Graded from	filings received through Mar 17, 2026 206 days before the rescans; latest periodic filing 10-Q received Aug 11, 2026	
Last close	\$14.64 2026-10-06; market equity \$59.1M	
Price used in grade	None	

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	
	20132014201520162017201820192020202120222023202420252026

Business, in the company's words

opening of Item 1 of the 10-K received Mar 17, 2026

-License Agreements-License Agreement between Eloxx and Almirall." The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as our product candidates, if approved.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability						
Gross profitability		not computable	32.2%		one or more required annual facts are missing	

Return on invested capital	not computable	9.3%				prior invested-capital observation is 1096 days earlier
Accruals ratio	not computable	(6.6%)				prior assets observation is 1096 days earlier
Gross margin stability, five years	not computable	2.8 pts				five annual gross margins are required; found 0
Solvency, sleeve percentile 97.2						
Twelve-month failure probability	not computable	0.07%				four consecutive discrete net-income quarters are required; found 4
Altman Z double-prime		(209.70)	(0.31)	98.1	756	2025-12-31
Net debt to EBITDA	not computable	1.82x				EBITDA must exceed \$100,000
Interest coverage	not computable	(4.51x)				latest aligned inputs end 2017-12-31; latest annual assets end 2025-12-31
Current ratio		0.31x	2.96x	96.2	839	2025-12-31
Growth and financing						
Revenue growth, three-year compound	not computable	10.0%				four annual observations are required; found 3
Free cash flow growth, three-year compound	not computable	10.9%				four consecutive annual FCF observations are required; found 11
Reinvestment rate	not computable	37.1%				NOPAT must exceed \$100,000
Asset growth, three years	not computable	2.1%				four consecutive annual observations are required
Net share issuance, one year	not computable	2.5%				prior share count is 1081 days earlier

Warnings

4 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 4 NT 10-K/Q filings in the last eight quarters
Thin data	2 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the \$100,000 validity floor
Fortress balance sheet	cash minus debt is 3,785,000 USD; Altman Z is not used

What the price implies

at the 2026-10-06 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	not computable	8.0%	
Distance from 52-week high	(27.6%)	(31.4%)	56
EBIT to enterprise value	(2,053.9%)	(1.5%)	1
Free cash flow yield	(52.1%)	(1.0%)	11
Book value to price	0.76	0.28	79
Sales to price	0.00	0.31	0
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	not computable	(0.14)	

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	59 (10-Q received Aug 11, 2026)
Median daily dollar volume, 63 sessions	\$531,799

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	operating income	us-gaap:OperatingIncomeLoss	-\$6.4M	2025-12-31	2026-03-17	10-K	0001193125-26-108687
2	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	-\$6.0M	2025-12-31	2026-03-17	10-K	0001193125-26-108687
3	income tax	us-gaap:IncomeTaxExpenseBenefit	\$0	2025-12-31	2026-03-17	10-K	0001193125-26-108687
4	total debt	us-gaap:LongTermDebt	\$1.0M	2025-12-31	2026-03-17	10-K	0001193125-26-108687
5	book equity	us-gaap:StockholdersEquity	-\$11.9M	2025-12-31	2026-03-17	10-K	0001193125-26-108687
6	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$4.8M	2025-12-31	2026-03-17	10-K	0001193125-26-108687
7	total debt	us-gaap:LongTermDebt	\$11.7M	2022-12-31	2023-03-31	10-K	0000950170-23-011360
8	book equity	us-gaap:StockholdersEquity	-\$10.7M	2022-12-31	2026-03-17	10-K	0001193125-26-108687
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$19.2M	2022-12-31	2023-03-31	10-K	0000950170-23-011360
10	net income	us-gaap:NetIncomeLoss	-\$6.0M	2025-12-31	2026-03-17	10-K	0001193125-26-108687
11	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$6.3M	2025-12-31	2026-03-17	10-K	0001193125-26-108687
12	assets	us-gaap:Assets	\$5.3M	2025-12-31	2026-03-17	10-K	0001193125-26-108687
13	assets	us-gaap:Assets	\$21.1M	2022-12-31	2023-03-31	10-K	0000950170-23-011360
14	current assets	us-gaap:AssetsCurrent	\$5.3M	2025-12-31	2026-03-17	10-K	0001193125-26-108687

15	current liabilities	us-gaap:LiabilitiesCurrent	\$17.2M	2025-12-31	2026-03-17	10-K	0001193125-26-108687
16	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$300.6M	2025-12-31	2026-03-17	10-K	0001193125-26-108687
17	liabilities	us-gaap:Liabilities	\$17.2M	2025-12-31	2026-03-17	10-K	0001193125-26-108687
18	depreciation amortization	us-gaap:Depreciation	\$0	2025-12-31	2026-03-17	10-K	0001193125-26-108687
19	operating income	us-gaap:OperatingIncomeLoss	-\$20.4M	2017-12-31	2020-03-06	10-K	0001564590-20-009148
20	interest expense	us-gaap:InterestAndDebtExpense	\$824,000	2017-12-31	2018-03-16	10-K	0001193125-18-086028
21	revenue	us-gaap:Revenues	\$0	2025-12-31	2026-03-17	10-K	0001193125-26-108687
22	revenue	us-gaap:Revenues	\$182,229	2014-06-30	2016-10-13	10-K	0001144204-16-128038
23	revenue	us-gaap:Revenues	\$200,000	2012-06-30	2012-10-26	10-K/A	0001144204-12-057875
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$66,000	2022-12-31	2023-03-31	10-K	0000950170-23-011360
25	depreciation amortization	us-gaap:Depreciation	\$77,000	2022-12-31	2023-03-31	10-K	0000950170-23-011360
26	operating income	us-gaap:OperatingIncomeLoss	-\$34.4M	2022-12-31	2023-03-31	10-K	0000950170-23-011360
27	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDiscontinuedOperations	\$64,112,000	2022-12-31	2023-03-31	10-K	0000950170-23-011360
28	income tax	us-gaap:IncomeTaxExpenseBenefit	\$0	2022-12-31	2023-03-31	10-K	0000950170-23-011360
29	current assets	us-gaap:AssetsCurrent	\$20.1M	2022-12-31	2023-03-31	10-K	0000950170-23-011360
30	current liabilities	us-gaap:LiabilitiesCurrent	\$23.1M	2022-12-31	2023-03-31	10-K	0000950170-23-011360
31	current assets	us-gaap:AssetsCurrent	\$43.5M	2021-12-31	2023-03-31	10-K	0000950170-23-011360
32	current liabilities	us-gaap:LiabilitiesCurrent	\$10.0M	2021-12-31	2023-03-31	10-K	0000950170-23-011360
33	assets	us-gaap:Assets	\$45.1M	2021-12-31	2023-03-31	10-K	0000950170-23-011360
34	assets	us-gaap:Assets	\$26.5M	2020-12-31	2022-03-30	10-K	0001564590-22-012683
35	shares outstanding	dei:EntityCommonStockSharesOutstanding	5,071,935	2026-03-12	2026-03-17	10-K	0001193125-26-108687
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	2,166,356	2023-03-27	2023-03-31	10-K	0000950170-23-011360